Table 1.
Studies | Adverse outcomes | Follow-up period |
---|---|---|
Berger (2008) [11] | Death | 2 years |
Lemesle (2016) [12] | Composite endpoints, all-cause death, cardiac death, MI, stroke, BARC type ≥ 3 bleeding | 2 years |
Park (2016) [13] | Composite endpoints, all-cause death, cardiac death, MI, stroke, BARC type ≥ 3 bleeding | 3 years |
MI myocardial infarction, BARC bleeding according to the Bleeding Academic Research Consortium; composite outcomes include: cardiovascular death, MI and stroke